Six of seven: the peptide vote is in

We wrote about this meeting back when it was still a date on the calendar. It has now happened. On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee met at the agency's campus in Silver Spring and voted on the seven peptides in front of it. The short version: six got a favorable recommendation for the 503A bulks list, the roster of substances licensed compounding pharmacies are allowed to work with. One did not.

What the committee decided

BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon all cleared the vote. The lone holdout was emideltide, better known as DSIP, the sleep peptide, which the panel declined to recommend. Most of the votes were close. DSIP failed by a single member.

That is the headline, and it is a real shift in the regulatory posture we described a few weeks ago. A favorable committee vote is the step that puts a substance on track toward legitimate pharmacy compounding rather than the gray market. For six of these names, that track just got a little clearer.

The part worth slowing down for

Here is the detail that makes this more interesting than a scoreboard. Going into the meeting, the FDA's own scientists had reviewed the same evidence and reached the opposite conclusion. Their briefing materials recommended against adding any of the seven, citing safety and effectiveness data they considered insufficient. The committee agreed with its own staff on exactly one peptide, the one it rejected.

So the panel did not vote yes because the science had suddenly arrived. Several members said as much. They acknowledged the gaps and voted to recommend anyway, framing it less as an endorsement than as a response to a market that already exists. People are using these compounds. The argument was that a regulated pathway, with pharmacies that answer to someone, beats the unregulated channels those people use now.

The agency's staff kept pressing a specific worry: when a prescription is written for one of these, what does the patient actually receive? One FDA comment compared the situation to a Volvo built to NASCAR specs, the same familiar name covering products that can differ in amino acid sequence and molecular weight. The question was not only whether a peptide works. It was whether two vials labeled the same way even contain the same thing.

What a recommendation is not

None of this is settled. The committee's votes are advisory, and advisory means exactly that. Before any of the six can be legally compounded, the FDA has to run a separate notice-and-comment rulemaking, weigh the full record, and issue a rule. The agency can accept the panel's advice, modify it, or set it aside. That process runs on the order of many months, often well past a year.

And the older distinction still holds. Being permitted to compound a substance is a statement about manufacturing oversight and acceptable risk. It is not a verdict on benefit. A peptide can clear this bar and still have very little controlled human data behind any particular use, which is roughly where most of these names sit today. The vote widened the legal door. It added nothing to the evidence on the other side of it.

How to hold it

The useful frame from last time hasn't changed, and this week made it concrete. Two clocks are running at different speeds. Regulation moved this month, in a committee room, in a single afternoon of votes. Evidence moves in trials, over years, and it did not move at all on July 23. When the fast clock jumps ahead, the honest read is not "it passed, so it must be good." It's that a market already in motion is being pulled toward oversight, which is worth wanting on its own terms and separate from whether any of it does what people hope.

Six of seven is a genuine story about access. It is not yet a story about proof. Those remain two different things, and the gap between them is the part still worth watching.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.